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ABSTRACT
Background: Several limitations of current 
antiretroviral therapy (ART) programmes will 
continue to push patients towards the use of plants to 
manage HIV/AIDS. However, evidence about the 
use of anti-HIV plants is anecdotal. 
Objectives: Search the literature for research articles 
that document plants with anti-HIV properties; and 
document the taxonomic families and species of 
plants with anti-HIV properties, their active 
ingredients, and modes of action against HIV. 
Methodology: Literature search for the key words 
“plants with anti-HIV activity” in PubMed Central.
Results: The literature survey documented about 36 
plant families containing 46 plant species with 
known anti-HIV active compounds and known 
modes of action. Anti-HIV active compounds such 
as terpenoids, coumarins, polyphenols, tannins, 
proteins, alkaloids, and biflavonoids inhibit various 
steps of the HIV  life cycle.
Discussion: Most studies that revealed anti-HIV 
active compounds and their modes of action were 
conducted outside Africa. A new initiative under 
NEPAD will help validate African medicinal plants 
used to manage HIV/AIDS.
Conclusions: The review presents evidence that 
several plant families and species contain anti-HIV 
active compounds that could be developed into 
newer drugs to manage HIV/AIDS. This evidence 
should persuade further research and public interest 
into the isolation of anti-HIV active compounds 
from plants. 
Recommendation: There is an urgent need to fast-
track HIV/AIDS clinical trials of candidate drugs 
developed from novel compounds isolated from 
plants.
BACKGROUND
At the end of 2009, 68% of the 330,000 Zambians 
needing antiretroviral therapy (ART) were 
receiving it and a third of all health facilities in the 
1
country were able to offer treatment . Despite this 
impressive progress, Zambia's ART programme is 
like a candle in the wind as it battles to glimmer 
against the inevitable possibility of dying from 
another form of AIDS- 'Acquired Income 
Deficiency Syndrome'. There are concerns that the 
country's free public sector ART programme is not 
sustainable due its heavy reliance on donor funds. 
Besides funding, access to treatment in Zambia is 
challenged by inadequacy of the healthcare system, 
which suffers from high patient numbers, lack of 
physical space and infrastructure, and attrition of 
2,3
health workers . Notably, there is a critical shortage 
of doctors. In 2006, there were only about 646 
doctors; this was under a third of the doctor-patient 
ratio recommended by the World Health 
 2Organization (WHO) . 
ART is also associated with serious side-effects now 
causing new forms of stigma. For example, ART has 
been associated with the development of 
lipodystrophy (LD). Lipodystrophy is characterized 
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by peripheral fat loss (lipoatrophy) and central fat 
accumulation which may result in thin facial pads, 
thin arms and legs, pot-bellies, and 'buffalo humps', 
4
leaving patients stigmatized . Thus, while 
acknowledging that current antiretroviral drugs are 
vitally important in improving the quality and 
prolonging the life of HIV/AIDS patients, the drugs 
still have many disadvantages including resistance, 
toxicity, limited availability, and lack of any curative 
5
effect . Limitations of conventional ART continue to 
open new avenues in the use of ethnomedicinal 
plants for the management of HIV/AIDS. 
The World Health Organization (WHO) 
recommended that traditional healers be included in 
6national responses to HIV/AIDS . As early as 1989, 
WHO had already voiced the need to evaluate 
ethnomedicines for the management of HIV/AIDS: 
“In this context, there is need to evaluate those 
elements of traditional medicine, particularly 
medicinal plants and other natural products that 
might yield effective and affordable therapeutic 
agents. This will require a systematic approach”, 
7stated a memorandum of the WHO .
Although there are a good number of reports on 
traditional uses of plants to treat various diseases, 
knowledge of herbal remedies used to manage 
HIV/AIDS is scanty, impressionistic and not well 
8,9,10documented . Zambia has rich plant biodiversity 
and a long tradition of medicinal use of plants. 
Several of these plants may contain novel anti-HIV 
compounds. Thus, it is important to search for novel 
antiretroviral agents that can be added to or replace 
11the current arsenal of drugs against HIV . A 
literature survey of plants with anti-HIV activity is 
an important prerequisite in the quest to quicken the 
search for novel HIV/AIDS treatments in Zambia 
and beyond. Therefore, the current effort is a modest 
attempt to review the taxonomic families and 
species of plants with anti-HIV active compounds 
and their modes of action. 
OBJECTIVES
The goal of the current study is to provide empirical 
evidence that several plants possess anti-HIV active 
compounds, help refocus the attention of 
researchers towards the study of herbal plants with 
anti-HIV activity, and re-inspire public and research 
interest in the use of plants with anti-HIV 
properties. This goal was approached through the 
following objectives:
1. To search the literature for research articles 
that document plants with anti-HIV 
properties;
2. To document the taxonomic families and 
species of plants with anti-HIV properties, 
their active ingredients, and modes of 
action against HIV. 
METHODOLOGY
We searched for the key words “plants with anti-
HIV activity” in PubMed Central, the United States 
of America National Library of Medicine's digital 
archive of biomedical and life sciences journal 
literature. Within the process of the literature search 
that lasted 2 months, we reviewed only-peer 
reviewed journal articles written in English 
language (excluding journal abstracts and 
conference abstracts), from all over the world. Pay-
to-view articles were not included.  Taxonomic 
families and species of plants, active compounds 
and their modes of action, were documented from 
primary literature sources.  The search was not 
restricted to any time frame but did not cover the 
period before 1989. The inclusion criteria were: (a) 
plants should have been known by their scientific 
names; (b) anti-HIV active ingredients were 
isolated and known; and (c) mode of action for 
active ingredients were known. 
RESULTS
 
Of the 150 journal articles found during the search, 
only 47 met our pre-determined inclusion criteria. 
Most of the studies, especially from Africa, were not 
included as they failed to meet the  inclusion 
criteria. Therefore, out of the total number of 
articles reviewed, only about a third were included 
in this study.
The literature survey documented about 36 plant 
families containing 46 plant species with known 
anti-HIV active compounds and known modes of 
action. Several anti-HIV active compounds such as 
terpenoids, coumarins, polyphenols, tannins, 
proteins, alkaloids, and biflavonoids inhibit various 
steps of the virus life cycle. Details of the plant 
families and species, active compounds, modes of 
179
action, and literature sources are listed in Table 1. Five chemical compounds were found to interfere with HIV 
16, 23,35,43,46
entry into cells . Most of the entry inhibitors were agglutinins from Galanthus nivalis and 
16 23
Hippeastrum . A coumarin called wedelolactone inhibited cell-to-cell transmission of HIV-1 . BanLec, a 
43
jacalin-related lectin that binds to glycosylated viral envelopes blocked HIV-1 entry into cells , and 
Phytolacca americana pokeweed antiviral protein (PAP), a 29 KDa ribosome-inactivating protein that 
46removes adenine from rRNA was found to be a potent microbicide .
Table 1: Plants with active compounds and modes of action against HIV
Family
species Active constituents Mechanism of action References
Acanthaceae
Andrographis paniculata Aqueous extracts of leaves
Diterpene lactones (andrographolide)





replication and syncytia 





































Plant lectins: G. nivalis agglutinin 
(GNA), 
 
Hippeastrum hybrid agglutinin (HHA), 




Stops spread of HIV among 
lymphocytes; most 
prominent anti-HIV activity 
is found among MBLs; 
GNA has specificity for 
terminal α(1-3)-linked 
mannose residues; HHA 
recognizes both terminal and 










Rhus succedanea L. 
 
 





























































































dicaffeoylquinic acid, and 1-
methoxyoxalyl-3,5-dicaffeoylquinic acid
 
Wedelolactone, a coumarin derivative; 
orobol (an isoflavone derivative)
 















Arnebia euchroma (Royle) Jonst
 
 
Monosodium and monopotassium salts 
of isomeric caffeic acid tetramer
 
 






























































































Inhibits reverse transcriptase 
 
 










































Gallic acid and galloyl glucose
 
 




Inhibits HIV reverse 
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BanLec, a jacalin-related lectin
 
 
Blocks HIV entry, hence is a 
good microbicide; potent 

















Polyphenols protect cell 
membranes against free 
radical-induced damage; 
gallotannins have anti-burn 
properties; 3,4,5-tri-O-
galloylquinic acids have anti-

























Phytolacca Americana L  
 














Crataegus pinatifida   
 
 
Geum japonicum  
 
Uvaol and ursolic acid  
 
 
Maslinic acid  
 
Inhibits HIV-1 protease  
 






About 28 different chemical compounds were 
known to be active against HIV reverse 
transcriptase and replication. Some of these HIV 
reverse transcriptase inhibitors included: 
1 7bi f lavonoids  f rom Rhus  succedanea ,  
18michellamines from Ancistrocladus korupensis , 
lanostane-type triterpenes from Polyalthia 
19 20suberosa , suksdorfin from Lomatium suksdorfii , 
24caffeic acids from Arnebia euchroma , celasdin B 
26from Celastrus hindsii , calanolide A from 
29
Callophyllum cordato-oblongum , gallotannin 
33
from Combretum molle , flavonone-xanthone 
36
glucoside from Swertia franchetiana , protostanes 
38
from Garcinia speciosa , catechins from Detarium 
40
microcarpum , cepharanthine from Stephania 
4 2
cepharantha ,  gal loyquinic  acids  from 
44
Myrothamnus flabellifolius , velutin isolated from 
4 5
Flammulina velut ipes ,  o leanolic  from 
51
Xanthoceras sorbifolia , nigranoic acid from 
52
Schisandra sphaerandra , triterpene lactone from 
182
53Kadsura lancilimba , and harmine isolated from 
54Symplocos setchuensis .
Three of the identified active compounds were 
known to be HIV integrase inhibitors: flavonoid 
gallate ester from Acer okamotaanum of the 
14
Aceraceae family , dicaffeoylquinic acids from 
22
Achyrocline satureioides of the Asteraceae family , 
and curcumin from Curcuma longa in the 
56Zingiberaceae family . Six active compounds were 
found to be HIV protease inhibitors: water-soluble 
37
lignins from Inonotus obliquus , uvaol and ursolic 
47
acid from Crataegus pinatifida , maslinic acid from 
48
Geum japonicum , limonin and nomilin from 
49
Citrus spp. , camellia-tannin H from Camellia 
55 56
japonica , and curcumin , which was also shown to 
56
be active against HIV-1 integrase .
Two active compounds were found to inhibit 
syncytia formation, a property of HIV that makes 
infected and healthy CD4 cells to fuse and form one 
giant cell with as many as 500 nuclei. Syncytia-
inhibiting compounds included: diterpene 
13 18lactones , and michellamines A and B . Seven plant 
compounds prevented HIV-induced cytopathic 
1 5e ff ec t :  su l f a t ed  l en t inan ,  su l fona ted  
21 25polysaccharides , xantholhumol , (+)-calanolide 
29 31 30 50
A , guttiferone A , palicourein , and nitidine . 
41Magnolia spp.  and the Namibian resurrection plant 
44Myrothamnus flabellifolius  were found to have 
anti-oxidant properties. 
DISCUSSION
The data presented above are mostly from 
laboratory studies conducted in Asia, America and 
Europe. Most research on the use of medicinal 
plants in Africa does not reveal the active 
ingredients and their modes of action against HIV. 
For example, a study in Tanzania documented about 
74 different plant species used in the management of 
57
HIV/AIDS  but the researchers did not go further to 
isolate the active ingredients from such plants. 
Isolation of active ingredients from plants and 
determination of their modes of action require 
expensive equipment which most government-
8,9funded research laboratories in Africa are lacking .
Responding to the compelling need for evidence 
regarding traditional medicines, NEPAD and 
Southern African Network for Biosciences 
(SANBio) launched a flagship project to validate 
ethnomedicines for the affordable treatment of 
HIV/AIDS and related opportunistic infections. 
Under this project, Zambia's Sondashi formula (SF-
2000), invented from four plants by Dr. Ludwig 
Sondashi, is undergoing scientific validation at the 
Council for Scientific and Industrial Research 
(CSIR) in Pretoria, South Africa. Anti-HIV active 
compounds from the plants have been isolated, and a 
clinical trial is now being planned.
On the other hand, the inclusion of anti-HIV herbal 
medicines in official HIV/AIDS policy is an 
extremely sensitive and contentious issue. It is 
sensitive because anti-HIV plant products can easily 
become a scapegoat for denial and inertia to roll-out 
ART. It is also contentious because in various 
resource-poor settings, government-sponsored ART 
programmes discourage the use of traditional 
medicines, fearing that the efficacy of antiretroviral 
drugs may be inhibited by such natural products, or 
that their pharmacological interactions could lead to 
toxicity. 
Although no plant-derived drug is currently in 
clinical use to treat HIV/AIDS, phase II clinical 
58trials were conducted for calanolide A . The data 
from these clinical trial are not known to us. Other 
than calanolide A and two other molecules code-
named PA-457 and PA-334B, our literature survey 
revealed no other report of clinical trials with anti-
HIV drugs derived from plants. Prior to 2005, there 
had been a decline in the use of plant products as 
59
starting materials for drug discovery . The lack of 
interest in utilizing plant products was attributed to 
rediscovery problems due to technical difficulties, 
issues of access and benefit sharing, and intellectual 
property rights, especially when working with 
59plants found across national borders and cultures . 
CONCLUSION
Plants are an important source of anti-HIV chemical 
compounds, and several plant families and species 
contain anti-HIV active compounds that could be 
developed into newer drugs to manage HIV/AIDS. 
Therefore, the current literature survey provides an 
evidence-based contribution to our understanding of 
plants that can be used in the management of 
HIV/AIDS. This evidence should persuade further 
research and public interest into the isolation of anti-
HIV active compounds from plants. 
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RECOMMENDATIONS
There is need to increase the screening of plants 
based on ethnopharmacological data and indigenous 
knowledge; this will quicken the search for novel 
anti-HIV compounds. There is also an urgent need to 
fast-track HIV/AIDS clinical trials of candidate 
drugs developed from novel compounds isolated 
from plants.  Post-genomics, phylogenetic analysis 
and other bioinformatics tools may shed light on 
other related plants that may contain similar active 
compounds.
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